Atlas Trials

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Clinical trial NCT06335927 · UNKNOWN

Trial details

NCT number
NCT06335927
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Intrahepatic Cholangiocarcinoma
Start date
2023-05-11
Primary completion
2025-05-10
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.